Relapsing Multiple Sclerosis (RMS) Active Not Recruiting Phase 3 Trials for Teriflunomide (DB08880)

Also known as: Multiple Sclerosis Relapse / Relapsed Multiple sclerosis / Relapsing Multiple Sclerosis / Multiple sclerosis flare

IndicationStatusPhase
DBCOND0044896 (Relapsing Multiple Sclerosis (RMS))Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03277248A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)Treatment
NCT03277261A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)Treatment
NCT02792218Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple SclerosisTreatment